Sanofi's Amlitelimab: Clinical Success, Market Disappointment

Sanofi's experimental atopic dermatitis drug, amlitelimab, met trial goals but disappointed investors by falling short of blockbuster Dupixent's efficacy, sending shares plunging and raising concerns about the company's pipeline post-2031 patent expiry.